Sugi Predict

Sugi Predict / Compounds / SCHEMBL1993391

SCHEMBL1993391

SCHEMBL1993391

CC(c1cc2ncccc2nc1-c1cccc(F)c1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.39
▸ CYP1A2 P05177 3/20 0.39
▸ CYP3A4 P08684 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ TGFBR1 P36897 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ KDM5B Q9UGL1 1/20 0.38
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ MAOB P27338 1/20 0.37
▸ BCHE P06276 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ DHODH Q02127 2/20 0.37
▸ MAPK14 Q16539 6/20 0.36
▸ MAPK10 P53779 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12564510 0.92 CYP1A2 (0.36) USP2CYP1A2CYP3A4TSHRALDH1A1
SCHEMBL1994712 0.85 MBNL1 (0.40) ALDH1A1TGFBR1SMN1; SMN2KDM5BDHODH
SCHEMBL15302894 0.84 PIK3CD (0.46) USP2CYP1A2CYP3A4TSHRALDH1A1
SCHEMBL4175806 0.82 ADORA2A (0.40) USP2CYP1A2CYP3A4TSHRALDH1A1
SCHEMBL1989718 0.80 DHODH (0.37) ALDH1A1TGFBR1SMN1; SMN2KDM5BDHODH
SCHEMBL1988633 0.79 BCHE (0.44) USP2CYP1A2CYP3A4TSHRALDH1A1
SCHEMBL1990582 0.79 BCHE (0.44) USP2CYP1A2CYP3A4TSHRALDH1A1
SCHEMBL4181554 0.77 PIK3CD (0.46) ALDH1A1DHODH
SCHEMBL4181555 0.77 PIK3CD (0.46) ALDH1A1DHODH
SCHEMBL1990306 0.74 TOP1 (0.38) ALDH1A1TGFBR1SMN1; SMN2HSD17B10DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633313-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-01-21 — — US disclosed
US-8633313-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-01-21 — — US disclosed
US-8633313-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-01-21 — — US disclosed
EP-2513109-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2012-10-24 — — EP disclosed
US-20110152296-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-06-23 — — US disclosed
US-20110152296-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-06-23 — — US disclosed
WO-2011075628-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-06-23 — — WO disclosed
WO-2011075628-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-06-23 — — WO disclosed
US-20110152296-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152296-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 USP2 1124/4885CYP1A2 2390/4885CYP3A4 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.